BioCentury
ARTICLE | Finance

Fast inflections

Why Longitude Capital joined Cydan's investor syndicate

October 20, 2017 6:45 PM UTC

Longitude Capital joined Cydan Development Inc.’s syndicate with the expectation that spinouts from the rare disease accelerator can deliver returns within three to five years.

The company sources rare disease assets from academia, not-for-profits and industry and funds preclinical and sometimes early clinical development, with the goal of spinning out the most viable programs. ...

BCIQ Company Profiles

Cydan II Inc.

Vtesse Inc.